Oxford Biomedica plc (LON:OXB) Receives Average Rating of “Moderate Buy” from Analysts

Oxford Biomedica plc (LON:OXB) has received an average rating of “Moderate Buy” from the seven ratings firms that are currently covering the stock, Marketbeat Ratings reports. One equities research analyst has rated the stock with a hold recommendation and six have assigned a buy recommendation to the company. The average 12-month target price among analysts that have updated their coverage on the stock in the last year is GBX 600.04.

OXB has been the topic of several research reports. Royal Bank Of Canada dropped their price objective on shares of Oxford Biomedica from GBX 1,170 to GBX 1,140 and set an “outperform” rating on the stock in a report on Wednesday, June 24th. Jefferies Financial Group reiterated a “buy” rating and issued a GBX 8.27 target price on shares of Oxford Biomedica in a research note on Tuesday, June 2nd.

Oxford Biomedica Price Performance

Shares of Oxford Biomedica stock opened at GBX 643.06 on Tuesday. The company has a debt-to-equity ratio of 162.16, a current ratio of 2.20 and a quick ratio of 1.67. Oxford Biomedica has a fifty-two week low of GBX 350.50 and a fifty-two week high of GBX 952. The firm has a fifty day moving average price of GBX 615.69 and a two-hundred day moving average price of GBX 663.77. The company has a market cap of £778.34 million, a PE ratio of -23.89 and a beta of 1.12.

Oxford Biomedica Company Profile

Oxford Biomedica (LSE: OXB) is a quality and innovation-led cell and gene therapy CDMO with a mission to enable its clients to deliver life changing therapies to patients around the world.

One of the original pioneers in cell and gene therapy, the Company has more than 25 years of experience in viral vectors; the driving force behind the majority of gene therapies. The Company collaborates with some of the world’s most innovative pharmaceutical and biotechnology companies, providing viral vector development and manufacturing expertise in lentivirus, adeno-associated virus (AAV) and adenoviral vectors.